Advanced HCC: When to Switch to 2L Treatment - Case Presentation
By
COR2ED The Heart of Medical Education
FEATURING
Timon Vandamme
By
COR2ED The Heart of Medical Education
FEATURING
Timon Vandamme
Programme description:
Explore treatment selection and optimal sequencing after progression on immunotherapy in this patient case video. Follow a patient's journey through advanced HCC on treatment selection and sequencing presented by Prof. Dr Timon Vandamme.
Go to the interactive version of this patient case video: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-2nd-line/ where you will interact and engage with valuable information, challenging questions, and clickable resources. You'll choose your preferred 1st line treatment option for this patient, decide when to switch to 2nd line treatment, and which 2nd line option to recommend.
Clinical Takeaways
- IO based treatments are the first choice for patients with advanced HCC without active auto-immune disease and without liver transplant
- In case of slow progression, continuing IO based treatment should be considered for patients with HCC
- Research is ongoing to determine the best treatment options and sequencing after progression on IO based treatment for patients with HCC
This educational programme is supported by an Independent Medical Education Grant from Bayer
Publication date: December 2023
Explore treatment selection and optimal sequencing after progression on immunotherapy in this patient case video. Follow a patient's journey through advanced HCC on treatment selection and sequencing presented by Prof. Dr Timon Vandamme.
Go to the interactive version of this patient case video: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-2nd-line/ where you will interact and engage with valuable information, challenging questions, and clickable resources. You'll choose your preferred 1st line treatment option for this patient, decide when to switch to 2nd line treatment, and which 2nd line option to recommend.
Clinical Takeaways
- IO based treatments are the first choice for patients with advanced HCC without active auto-immune disease and without liver transplant
- In case of slow progression, continuing IO based treatment should be considered for patients with HCC
- Research is ongoing to determine the best treatment options and sequencing after progression on IO based treatment for patients with HCC
This educational programme is supported by an Independent Medical Education Grant from Bayer
Publication date: December 2023
Comments 0
Login to view comments.
Click here to Login
